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ABO BLOOD GROUP ANTIBODIES AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Stussi, G.1, Huggel, K.1, Schanz, U.1, Halter, J.1, Passweg, J.R.2,
Gratwohl, A.2, Seebach, J.D.1 1. University Hospital, Zuerich, Swit-
zerland; 2. University Hospital, Basel, Switzerland.
Aside from causing hemolytic reactions the ABO blood group
system does not have a major impact on the outcome after alloge-
neic hematopoietic stem cell transplantation (HSCT). However,
only limited studies have analyzed the importance of anti-A/B
antibodies after HSCT. In particular, after minor and bidirectional
ABO-incompatible HSCT, donor B lymphocytes may produce
anti-recipient ABO antibodies. We developed a new method using
ﬂow cytometry (FACS) to quantify anti-A/B antibodies after
HSCT. Repetitive serum samples of 16 patients (ABO-identical 5,
major 4, minor 4, bidirectional 3) receiving allogeneic HSCT were
analyzed by FACS and agglutination assay with a mean follow-up
time of 486 days (range: 22-810 days). Most patients received
HSCT for acute or chronic leukemia (AML 43%, CML 31%) and
in 50% of the cases peripheral blood was used as stem cell source.
In a preliminary analysis, we did not ﬁnd an elevation of anti-
recipient ABO-antibodies after minor or bidirectional ABO-in-
compatible HSCT. None of these patients had clinical signs of
hemolysis or bilirubin elevations. In general, anti-A/B IgM and
IgG gradually decreased after transplantation. However, in some
cases, posttransplant anti-A/B antibody levels approached donor
antibody levels, and in 2 additional patients, elevation of recipient
anti-A/B antibodies correlated with the incidence of relapse. All
data obtained by FACS analysis correlated well with the results
obtained by agglutination assays. In conclusion, no transient ele-
vation of anti-recipient ABO antibodies after minor ABO-incom-
patible HSCT was observed in 7 patients receiving minor or
bidirectional ABO-incompatible HSCT. The general reduction of
ABO antibody levels after HSCT might be a consequence of the
immunosuppressive regimen. In some cases, however, the reap-
pearance of recipient ABO antibodies seems to correlate with the
relapse of leukemic disease.
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TEMPORALLY DISCORDANT GRAFT VERSUS LEUKEMIA (GVL) AND
GRAFT VERSUS HOST (GVH) RESPONSES AFTER DONOR LYMPHOCYTE
INFUSION THERAPY FOR RELAPSED CHRONIC MYELOGENOUS LEUKE-
MIA
Hari, P.N., Drobyski, W.R. Medical College of Wisconsin, Milwaukee,
WI.
Separation of GVL and GVH reactivity after allogeneic hema-
topoietic stem cell transplantation remains an elusive clinical goal.
We have previously observed in murine models that GVL and
GVH reactivity can be dissociated based on temporal kinetics
whereby the GVL effect antedates GVHD allowing mice mice to
eliminate leukemia before they develop lethal GVHD (J Immunol
170:2003). To determine if this observation was relevant to man,
we examined the tempo of GVL and GVH reactivity in a cohort of
patients receiving DLI for relapsed CML where the kinetics of
these responses could be examined in the absence of the confound-
ing effects of the conditioning regimen and immunosuppressive
therapy. Between 1992-2002, 38 patients with relapsed CML after
allogeneic BMT from either HLA-identical sibling or unrelated
donors were treated with DLI. Patients were excluded if they did
not have both an antileukemic response and GVHD after DLI
(n  16) or were administered prolonged (2 weeks) IFN therapy
after DLI to control blood counts (n  4). The remaining 18
patients were in either accelerated phase 4/18 (22%), chronic phase
9/18 (50%), cytogenetic relapse 4/18 (22%), or molecular relapse
1/18 (5%) at time of DLI. All had sustained cytogenetic (CGR)
and/or molecular responses (MR)(Houston criteria) attributable to
DLI along with documented clinical GVHD. The median time to
earliest cytogenetic or molecular response was 53 days (20 -97)
while time to complete cytogenetic or molecular remission was 82
days (32 -230). The inital onset of GVHD occurred at a median of
59 days (32 -157) in the entire patient cohort. Eleven of 18 patients
had evidence of a CGR or MR that occurred a median of 22 days
(range 5-121)before onset of GVHD. In 4 patients a CGR or MR
was documented concurrently with GVHD, indicating that a GVL
response had already occurred before GVHD became clinically
evident, while in 3 patients GVHD developed before an antileu-
kemic response was observed. In 7 patients, the CGR or MR was
already complete before GVHD began and antedated the onset of
GVHD by a median of 14 days (range 0-84). These data indicate
that GVH and GVL responses are not synchronous events but can
occur with temporally discordant kinetics. These data also provide
rationale for therapeutic strategies designed to dissociate these two
events after allogeneic SCT by the targeted elimination of allo-
reactive donor T cells after the GVL effect has occurred but before
clinical GVHD has developed.
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CROSS-PROTECTIVE T CELL RESPONSES TO MURINE MYELOID LEU-
KEMIAS ARE REVEALED BY CHARACTERIZATION OF THE CD8 T CELL
REPERTOIRE
Lewandowski, A.M., Friedman, T.M., Castor, D., Korngold, R. Jeffer-
son Medical College, Kimmel Cancer Center, Philadelphia, PA.
Three heterologous c-myc retrovirus-transformed myeloid leu-
kemia lines (MMB 1.10, MMB2.18, and MMB3.19) of C57BL/6
(B6; H2b) origin were used to investigate graft-versus-leukemia
(GVL) activity in murine bone marrow transplantation models.
The transfer of B6 CD8 T cells, from mice appropriately pre-
sensitized to each individual myeloid leukemia, to bone marrow
reconstituted syngeneic recipients could mediate effective GVL
protection against the speciﬁc leukemic challenge. In addition,
MMB3.19-primed B6 CD8 T cells provided a cross-protective
GVL effect against challenge with the MMB1.10 and MMB2.18
cells. In order to better characterize the B6 CD8 T cell anti-
leukemia responses, T cell receptor V CDR3-size spectratype
analysis was performed after in vivo stimulation with each individ-
ual leukemia line. The spectratype results indicated both unique
and overlapping skewing patterns between the leukemia-reactive
populations, suggesting the recognition of both shared and distinct
tumor antigens. V 2, 11, and 12 families were uniquely involved
in the anti-MMB2.18 response, whereas involvement of the V 7
family was unique to the anti-MMB3.19 and MMB1.10 responses.
On the other hand, V 3 and 6 families were similarly skewed in
response to all three leukemia lines. These ﬁndings were translated
back to the in vivo model, whereby infusion of uniquely reactive
V subpopulations of presensitized B6 CD8 T cells caused sig-
niﬁcant GVL activity against challenge with the corresponding
leukemia line, after syngeneic bone marrow transplantation. How-
ever, signiﬁcant GVL protection was not observed in groups chal-
lenged with the non-overlapping leukemia lines. Conversely, infu-
sion of the shared reactive V3 and 6 subpopulations protected B6
recipients from challenge with all three MMB cell lines. These
results demonstrated that syngeneic CD8 T cell responses can be
generated that are targeted at either unique or shared myeloid
leukemia antigens. A better understanding of the precise nature of
these anti-leukemia responses and identiﬁcation of their corre-
sponding leukemia tumor antigens may provide insight into the use
of ex vivo stimulated autologous T cells for treatment of acute
(AML) and chronic (CML) myelogenous leukemia.
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DISTINCT DIFFERENCES IN GVHD EFFECTOR ACTIVITY AMONG DONOR
CD8 POPULATIONS: ENGRAFTMENT WITHOUT GVHD USING THE
FACILITATING CELL
Kazerounian, S., Glickman, J.N., Wright, R.D., Napoli, R., Colson,
Y.L. Brigham and Women’s Hospital/Harvard Medical School, Boston,
MA.
INTRODUCTION: Bone marrow transplantation (BMT) is the
current treatment of choice for a variety of hematologic disorders,
and solid tumors. However, graft-versus-host disease (GVHD) and
failure of engraftment have limited this treatment option to the
30% of patients with a closely matched donor. Removal of T cells,
and cells which express markers shared by T cells decreases the
severity of GVHD but increases the incidence of graft failure.
Poster Session I
55BB&MT
